Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 13/20 | 0.35 |
| ▸ | DRD4 | P21917 | 13/20 | 0.35 |
| ▸ | DRD3 | P35462 | 13/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24397848 | 0.87 | HSD11B1 (0.38) | ALDH1A1HSD11B1DRD2DRD4DRD3 | |
| SCHEMBL26929238 | 0.86 | DRD2 (0.34) | ALDH1A1DRD2DRD4DRD3LMNA | |
| SCHEMBL26941610 | 0.85 | MAPK1 (0.36) | ALDH1A1PTGDRPTGDR2LMNASMN1; SMN2 | |
| SCHEMBL26941611 | 0.85 | ALDH1A1 (0.37) | ALDH1A1DRD2DRD4DRD3LMNA | |
| SCHEMBL26941609 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HSD11B1PTGDR2DRD2DRD4 | |
| SCHEMBL26929241 | 0.84 | PDE2A (0.31) | — | |
| SCHEMBL26942730 | 0.84 | PPARD (0.36) | PTGDR2LMNA | |
| SCHEMBL26941636 | 0.83 | MAPT (0.39) | ALDH1A1HSD11B1DRD3LMNAMEN1 | |
| SCHEMBL24393978 | 0.83 | PDE2A (0.37) | — | |
| SCHEMBL24394026 | 0.82 | PPARD (0.36) | PTGDR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | claimed |
| EP-4237408-A1 | ITACONIC ACID DERIVATIVES | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | claimed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| EP-4237408-A1 | ITACONIC ACID DERIVATIVES | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | ALDH1A1 28/4885HSD11B1 175/4885PTGDR 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.